Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B

HBeAg status, HBV-DNA, ALT levels and treatment duration are the major determinants for the YMDD mutation during lamivudine therapy, and should be considered in designing the therapeutic strategy.